Literature DB >> 15975930

The proximal carboxyl-terminal domains of ADAMTS13 determine substrate specificity and are all required for cleavage of von Willebrand factor.

Jihui Ai1, Paula Smith, Shuwei Wang, Ping Zhang, X Long Zheng.   

Abstract

ADAMTS13 limits platelet-rich thrombosis by cleaving von Willebrand factor at the Tyr(1605)-Met(1606) bond. Previous studies showed that ADAMTS13 truncated after spacer domain remains proteolytically active or hyperactive. However, the relative contribution of each domain within the proximal carboxyl terminus of ADAMTS13 in substrate recognition and specificity is not known. We showed that a metalloprotease domain alone was unable to cleave the Tyr-Met bond of glutathione S-transferase (GST)-VWF73-H substrate in 3 h, but it did cleave the substrate at a site other than the Tyr-Met bond after 16-24 h of incubation. Remarkably, the addition of even one or several proximal carboxyl-terminal domains of ADAMTS13 restored substrate specificity. Full proteolytic activity, however, was not achieved until all of the proximal carboxyl-terminal domains were added. The addition of TSP1 2-8 repeats and two CUB domains did not further increase proteolytic activity. Furthermore, ADAMTS13 truncated after the spacer domain with or without metalloprotease domain bound GST-VWF73-H with a K(d) of approximately 7.0 or 13 nm, comparable with full-length ADAMTS13 (K(d) = 4.6 nm). Metalloprotease domain did not bind GST-VWF73-H detectably, but the disintegrin domain, first TSP1 repeat, Cys-rich domain, and spacer domain bound GST-VWF73-H with K(d) values of 489, 136, 121, and 108 nm, respectively. These proximal carboxyl-terminal domains dose-dependently inhibited cleavage of fluorescent resonance energy transfer (FRETS)-VWF73 by full-length ADAMTS13 and ADAMTS13 truncated after the spacer domain. These data demonstrated that the proximal carboxyl-terminal domains of ADAMTS13 determine substrate specificity and are all required for recognition and cleavage of von Willebrand factor between amino acid residues Asp(1595) and Arg(1668).

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15975930      PMCID: PMC2577221          DOI: 10.1074/jbc.M505513200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  34 in total

1.  Cleavage of ultralarge multimers of von Willebrand factor by C-terminal-truncated mutants of ADAMTS-13 under flow.

Authors:  Zhenyin Tao; Yongtao Wang; Huiwei Choi; Aubrey Bernardo; Kenji Nishio; J Evan Sadler; José A López; Jing-Fei Dong
Journal:  Blood       Date:  2005-03-17       Impact factor: 22.113

2.  Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura.

Authors:  X Zheng; D Chung; T K Takayama; E M Majerus; J E Sadler; K Fujikawa
Journal:  J Biol Chem       Date:  2001-09-13       Impact factor: 5.157

3.  A novel human metalloprotease synthesized in the liver and secreted into the blood: possibly, the von Willebrand factor-cleaving protease?

Authors:  K Soejima; N Mimura; M Hirashima; H Maeda; T Hamamoto; T Nakagaki; C Nozaki
Journal:  J Biochem       Date:  2001-10       Impact factor: 3.387

4.  Cloning, expression analysis, and structural characterization of seven novel human ADAMTSs, a family of metalloproteinases with disintegrin and thrombospondin-1 domains.

Authors:  Santiago Cal; Alvaro J Obaya; María Llamazares; Cecilia Garabaya; Víctor Quesada; Carlos López-Otín
Journal:  Gene       Date:  2002-01-23       Impact factor: 3.688

5.  Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases.

Authors:  A Veyradier; B Obert; A Houllier; D Meyer; J P Girma
Journal:  Blood       Date:  2001-09-15       Impact factor: 22.113

6.  Partial amino acid sequence of purified von Willebrand factor-cleaving protease.

Authors:  H E Gerritsen; R Robles; B Lämmle; M Furlan
Journal:  Blood       Date:  2001-09-15       Impact factor: 22.113

7.  Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura.

Authors:  G G Levy; W C Nichols; E C Lian; T Foroud; J N McClintick; B M McGee; A Y Yang; D R Siemieniak; K R Stark; R Gruppo; R Sarode; S B Shurin; V Chandrasekaran; S P Stabler; H Sabio; E E Bouhassira; J D Upshaw; D Ginsburg; H M Tsai
Journal:  Nature       Date:  2001-10-04       Impact factor: 49.962

8.  Mutations and common polymorphisms in ADAMTS13 gene responsible for von Willebrand factor-cleaving protease activity.

Authors:  Koichi Kokame; Masanori Matsumoto; Kenji Soejima; Hideo Yagi; Hiromichi Ishizashi; Masahisa Funato; Hiroshi Tamai; Mutsuko Konno; Kei Kamide; Yuhei Kawano; Toshiyuki Miyata; Yoshihiro Fujimura
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-14       Impact factor: 11.205

9.  ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions.

Authors:  Jing-fei Dong; Joel L Moake; Leticia Nolasco; Aubrey Bernardo; Wendy Arceneaux; Corie N Shrimpton; Alicia J Schade; Larry V McIntire; Kazuo Fujikawa; José A López
Journal:  Blood       Date:  2002-07-25       Impact factor: 22.113

10.  Cloning, expression, and functional characterization of the von Willebrand factor-cleaving protease (ADAMTS13).

Authors:  Barbara Plaimauer; Klaus Zimmermann; Dirk Völkel; Gerhard Antoine; Randolf Kerschbaumer; Pegah Jenab; Miha Furlan; Helen Gerritsen; Bernhard Lämmle; Hans Peter Schwarz; Friedrich Scheiflinger
Journal:  Blood       Date:  2002-07-12       Impact factor: 22.113

View more
  54 in total

1.  A model for single-substrate trimolecular enzymatic kinetics.

Authors:  Wei Chen; Cheng Zhu
Journal:  Biophys J       Date:  2010-05-19       Impact factor: 4.033

2.  Multiple domains of ADAMTS13 are targeted by autoantibodies against ADAMTS13 in patients with acquired idiopathic thrombotic thrombocytopenic purpura.

Authors:  X Long Zheng; Haifeng M Wu; Dezhi Shang; Erica Falls; Christopher G Skipwith; Spero R Cataland; Charles L Bennett; Hau C Kwaan
Journal:  Haematologica       Date:  2010-04-07       Impact factor: 9.941

3.  The ADAMTS13 metalloprotease domain: roles of subsites in enzyme activity and specificity.

Authors:  Rens de Groot; David A Lane; James T B Crawley
Journal:  Blood       Date:  2010-07-20       Impact factor: 22.113

4.  Gain-of-function ADAMTS13 variants that are resistant to autoantibodies against ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura.

Authors:  Cui Jian; Juan Xiao; Lingjie Gong; Christopher G Skipwith; Sheng-Yu Jin; Hau C Kwaan; X Long Zheng
Journal:  Blood       Date:  2012-01-30       Impact factor: 22.113

5.  Inhibitory autoantibodies against ADAMTS-13 in patients with thrombotic thrombocytopenic purpura bind ADAMTS-13 protease and may accelerate its clearance in vivo.

Authors:  S G Shelat; P Smith; J Ai; X L Zheng
Journal:  J Thromb Haemost       Date:  2006-08       Impact factor: 5.824

Review 6.  ADAMTS13 and microvascular thrombosis.

Authors:  Han-Mou Tsai
Journal:  Expert Rev Cardiovasc Ther       Date:  2006-11

7.  Correction of ADAMTS13 deficiency by in utero gene transfer of lentiviral vector encoding ADAMTS13 genes.

Authors:  Masami Niiya; Masayuki Endo; Dezhi Shang; Philip W Zoltick; Nidal E Muvarak; Wenjing Cao; Sheng-Yu Jin; Christopher G Skipwith; David G Motto; Alan W Flake; X Long Zheng
Journal:  Mol Ther       Date:  2008-10-28       Impact factor: 11.454

8.  Correction of murine ADAMTS13 deficiency by hematopoietic progenitor cell-mediated gene therapy.

Authors:  Pablo Laje; Dezhi Shang; Wenjing Cao; Masami Niiya; Masayuki Endo; Antoneta Radu; Nicole DeRogatis; Friedrich Scheiflinger; Philip W Zoltick; Alan W Flake; X Long Zheng
Journal:  Blood       Date:  2009-01-13       Impact factor: 22.113

9.  Transfusion of Platelets Loaded With Recombinant ADAMTS13 (A Disintegrin and Metalloprotease With Thrombospondin Type 1 Repeats-13) Is Efficacious for Inhibiting Arterial Thrombosis Associated With Thrombotic Thrombocytopenic Purpura.

Authors:  Mohammad S Abdelgawwad; Wenjing Cao; Liang Zheng; Nicole K Kocher; Lance A Williams; X Long Zheng
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-11       Impact factor: 8.311

10.  Characterization of conformation-sensitive antibodies to ADAMTS13, the von Willebrand cleavage protease.

Authors:  Zuben E Sauna; Chinyere Okunji; Ryan C Hunt; Tanvi Gupta; Courtni E Allen; Elizabeth Plum; Adam Blaisdell; Vahan Grigoryan; S Geetha; Robert Fathke; Kenji Soejima; Chava Kimchi-Sarfaty
Journal:  PLoS One       Date:  2009-08-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.